Quercetin for myocardial ischemia reperfusion injury: A protocol for systematic review and meta-analysis. Issue 26 (26th June 2020)

• Record Type: Journal Article
• Authors: Lu, Liying; Ma, Xiaocong; Zheng, Jinghui; Li, Lijuan; Yang, Wenna; Kong, Yixuan; Wang, Jie
• Is Part Of: Medicine. Volume 99:Issue 26(2020)
• Publication Date: 2020-06-26
• Subjects: meta-analysis -- myocardial ischemia reperfusion injury -- quercetin -- systematic review; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000020856
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: At present, there is no effective therapy for preventing myocardial ischemia reperfusion injury (MIRI), and it is inevitable. The methods how to effectively decrease MIRI have attracted the attention of medical researches in recent years. Quercetin is a part of natural flavonoids in plant polyphenols. Many studies have found that quercetin has a positive effect on MIRI. Methods: In order to clarify the effectiveness and potential mechanisms of quercetin for MIRI animals, we searched for animal studies of quercetin for MIRI in Wanfang data Information, Chinese National Knowledge Infrastructure, VIP information database, China Biology Medicine disc, EMBASE, PubMed, and Web of Science. Participant intervention comparator outcomes of this study are as flowing: P, rats in MIRI; I, received quercetin treatment merely; C, received only vehicle or no treatment; O, Main outcomes are myocardial infarction size and markers of myocardial injury. Additional outcomes are serum indices or protein levels tied to the mechanisms of quercetin in myocardial l/R injury. Review Manager 5.2 software and Stata14.0 will be used for data analysis. SYRCLE's risk of bias tool will be used for risk of bias analysis of animal studies. Discussion: This preclinical systematic review and meta-analysis will evaluate the effects and mechanisms of quercetin for MIRI animals, and provide more evidence-based guidance for transforming basic research into clinical treatment. Trial registration: INPLASY202050067, registered on 16/5/2020. Abstract : Supplemental Digital Content is available in the text